Differentiating lymphoma progression from benign lesions: features of incident [18F]FDG-avid foci on interim and end-of-treatment PET/CT

Read full text Summarise with VIRAT
Authors: Jingshi Yang, Zhuzhong Cheng, Ying Kou
Cited by: 0
References: 37

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective This study aimed to identify distinguishing characteristics of new lesions on interim or end-of-treatment [ 18 F]FDG PET/CT scans to differentiate lymphoma-related from benign lesions. Methods We retrospectively analyzed 20 patients who developed new lesions during chemotherapy and performed [ 18 F]FDG PET/CT scans in our department from January 2019 to December 2020. Parameters, including age, sex, lymphoma type, Lugano stage, treatment stage, SUVmax, TBR (tumor-to-blood pool ratio), lesion locations, and treatment evaluation, were compared between lymphoma-related and benign lesions to identify the factors associated with new lesions in lymphoma. ROC (receiver operating characteristic) Curve analysis was used to determine optimal cutoff values for differentiating lymphoma from benign lesions. Results Among the 20 patients, 11 had confirmed lymphoma progression, while 9 had benign lesions. The SUVmax of new lesions was significantly higher in lymphoma cases (median: 13.2 vs. 7.2, p = 0.02), as was the TBR (9.8 ± 5.8 vs. 4.1 ± 2.0, p = 0.01). No significant differences were observed in age, sex, lymphoma type, disease stage, treatment phase, new lesion locations, and baseline lesion characteristics between the two groups. ROC analysis identified optimal cutoff values of 7.8 for SUVmax (AUC = 0.803, 95% CI: 0.606–1.000) and 13.78 for TBR (AUC = 0.818, 95% CI: 0.628–1.000) to differentiate lymphoma from benign lesions. Conclusion SUVmax and TBR of new lesions on interim or end-of-treatment [ 18 F]FDG PET/CT scans are valuable discriminators between lymphoma and non-lymphoma lesions. These findings may aid in refining response assessment and guiding clinical decision-making.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Medical Imaging Techniques and Applications Hematological disorders and diagnostics

Publication details

Journal / source
Frontiers in Medicine
Volume
13
Pages
1809312–1809312
Publication date
30 March 2026
Language
EN